Journal article icon

Journal article

The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

Abstract:

Progress in understanding mechanisms of disease are necessary to usher in major changes in treatment. A new era in rheumatoid arthritis (RA) and related chronic autoimmune/inflammatory diseases is now beginning, with a variety of anti-TNFalpha treatments licensed for use in both RA and Crohn's disease. The rationale for this new treatment lies in an understanding that cytokines are critical, rate limiting molecules lying at the heart of the chronic autoimmune/inflammatory disease process. Thi...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1136/ard.58.2008.i27

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
Journal:
Annals of the rheumatic diseases
Volume:
58 Suppl 1
Issue:
SUPPL. 1
Pages:
I27-I31
Publication date:
1999-11-01
DOI:
EISSN:
1468-2060
ISSN:
0003-4967
Source identifiers:
481576
Language:
English
Keywords:
Pubs id:
pubs:481576
UUID:
uuid:ce96e1da-c171-43be-b72d-8aeed367d174
Local pid:
pubs:481576
Deposit date:
2014-08-29

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP